Proactive Investors - Run By Investors For Investors

CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies

CRISPR will use MaxCyte’s Flow Electroporation technology to deliver its components into T-cells, which are known to attack the body’s own cells that have been infected by viruses
gene editing
Today’s agreement expands the pair’s existing relationship

MaxCyte Inc’s (LON:MXCT) Flow Electroporation technology will be used by CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer after the pair signed a commercial licence agreement.

Doug Doerfler, MaxCyte chief executive, said the agreement was a “validation” of his firm’s technology, while CRISPR boss, Samarth Kulkarni, said he was pleased to have secured access to “the leading ex vivo delivery platform for both clinical and commercial use”.

READ: MaxCyte on track to start first-ever clinical trial before year-end

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

In this case, CRISPR will use the technology to deliver its components into T-cells which attack the body’s own cells that have been invaded by viruses or bacteria.

Today’s (Friday’s) tie-up expands the relationship between MaxCyte and CRISPR. The two signed a deal last year which allowed the latter to use Flow Electroporation as part of its efforts to develop treatments for haemoglobin-related diseases.

In return for supplying its technology, MaxCyte will receive milestone and sales-based payments in addition to other licensing fees.

“The expansion of our relationship with CRISPR Therapeutics signifies a key milestone for MaxCyte and our technology, providing further validation for the value and versatility of our technology as a leading enabler of next-generation cell-based therapies," said MaxCyte President and CEO Doug Doerfler.

“CRISPR Therapeutics is a leader in gene editing, and we are very pleased to expand our collaboration into new therapeutic areas as we continue to explore the use of our technology to advance medicines to market that will make a difference for patients.”

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018

Related Articles

knee physio
February 18 2019
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use